NCT03187795View on ClinicalTrials.gov

Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord Injury

PHASE2UnknownINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

April 3, 2019

Primary Completion Date

September 30, 2021

Study Completion Date

March 30, 2022

Conditions
Spinal Cord InjuriesUrinary Bladder, Neurogenic
Interventions
DRUG

Oxybutynin Chloride IR

Oxybutynin chloride immediate release (IR) 5 mg three times daily for 6 weeks

DRUG

Mirabegron

Mirabegron 25 mg tablet once daily for 2 weeks, followed by mirabegron 50 mg once daily for 4 weeks (Note: Placebo twice daily will be included with mirabegron once daily to match the three-time daily dosing of oxybutynin IR in the other intervention).

Trial Locations (1)

07052

RECRUITING

Kessler Institute for Rehabilitation, West Orange

Sponsors

Lead Sponsor

Kessler Foundation
All Listed Sponsors
collaborator

National Institute on Disability, Independent Living, and Rehabilitation Research

FED

lead

Kessler Foundation

OTHER

NCT03187795 - Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord Injury | Biotech Hunter | Biotech Hunter